References

mrj

Современная ревматология

Modern Rheumatology Journal

1996-70122310-158X

IMA-PRESS, LLC

10.14412/1996-7012-2017-4-73-78

mrj-798

Research Article

ОБЗОРЫ

REVIEWS

Анти-В-клеточная терапия у больных системной красной волчанкой

Anti-B cell therapy in patients with systemic lupus erythematosus

Цанян

М. Э.

Tsanyan

M. E.

maridoc@bk.ru

Соловьев

С. К.

Solovyev

S. K.

maridoc@bk.ru

Насонов

Е. Л.

Nasonov

E. I.

maridoc@bk.ru

Асеева

Е. А.

Aseeva

E. A.

maridoc@bk.ru

Меснянкина

А. А.

Mesnyankina

A. A.

maridoc@bk.ru

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», МоскваРоссияV.A. Nasonova Research Institute of Rheumatology, MoscowRussian Federation

2017

06012018

1147378

2018

Цанян М.Э., Соловьев С.К., Насонов Е.Л., Асеева Е.А., Меснянкина А.А.

Tsanyan M.E., Solovyev S.K., Nasonov E.I., Aseeva E.A., Mesnyankina A.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://mrj.ima-press.net/mrj/article/view/798

В статье представлен аналитический обзор литературы, посвященной вопросам применения ритуксимаба (РТМ) у больных системной красной волчанкой (СКВ). Рассмотрены современные взгляды на механизмы действия РТМ, его эффективность при различных органных повреждениях у больных с СКВ, в частности при волчаночном нефрите и поражении центральной нервной системы. Представлены данные, свидетельствующие о целесообразности применения РТМ у больных с высокой активностью СКВ, особенно при развитии рефрактерности к стандартной терапии глюкокортикоидами и цитостатиками. Уделено внимание стероид-сберегающему эффекту РТМ и снижению риска развития необратимых органных повреждений, ассоциированных с высокими дозами преднизолона. Обсуждаются возможность применения биоаналога РТМ (ацеллбия), а также перспективы терапии РТМ при ранней СКВ.

The paper presents an analytical literature review of the use of rituximab (RTM) in patients with systemic lupus erythematosus (SLE). It considers current views on the mechanisms of action of RTM, its efficacy in different organ damages in patients with SLE, particularly in those with lupus nephritis and central nervous system involvement. There is evidence suggesting that it is expedient to use RTM in patients with high activity of SLE, especially when the latter is refractory to standard therapy with glucocorticoids and cytostatics. Attention is paid to the steroidsparing effect of RTM and to the reduction of the risk of irreversible organ damages associated with high-dose prednisone. The paper discusses the possibility of using a RTM biosimilar (Acellbia) and prospects of RTM therapy for early SLE.

системная красная волчанкаанти-В-клеточная терапияритуксимаб

systemic lupus erythematosusanti-B therapyrituximab

References1

Насонов ЕЛ, редактор. Системная красная волчанка. В кн.: Клинические рекомендации. Москва: ГЭОТАР-Медиа; 2010. С.429–81. [Nasonov EL, editor. Systemic lupus erythematosus. In: Klinicheskie rekomendatsii [Clinical recommendations]. Moscow: GEOTAR-Media; 2010. P. 429–81.]

Mok CC. Treat-to-Target in systemic lupus erythematosus: are we there yet? Expert Rev Clin Pharmacol. 2016;9(5):675-80. doi: 10.1586/17512433.2016.1146589

Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti- CD20 monoclonal antibodies. Mol Immunol. 2007;44(16):3823-37. doi: 10.1016/j.molimm. 2007.06.151.

Bertsias G, Ionnidis JP, Boletis J, et al. Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008 Feb;67(2):195-205. Epub 2007 May 15. doi: 10.1136/ard.2010.130476.

Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010 Jul;69(7):1269-74. doi: 10.1136/ard. 2009.117200. Epub 2009 Nov 5.

Apostolopoulos D, Kandane-Rathnayake R, Raghunath S, et al. Independent association of glucocorticoids with damage accrual in SLE. Lupus Sci Med. 2016 Nov 22;3(1): e000157. eCollection 2016. doi: 10.1136/ lupus-2016-000157.

Bruce IN, O'Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2015 Sep;74(9): 1706-13. doi: 10.1136/annrheumdis-2013-205171.

Tarr T, Papp G, Nagy N, et al. Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus. Clin Rheumatol. 2017;36(2): 327-333. doi: 10.1007/s10067-016-3492-6.

Thamer M, Hernan MA, Zhang Y, et al. Prednisone, lupus activity, and permanent organ damage. J Rheumatol. 2009 Mar; 36(3):560-4. doi: 10.3899/jrheum.080828. Epub 2009 Feb 4.

Chambers SA, Allen E, Rahman A, et al. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford). 2009 Jun;48(6):673-5. doi: 10.1093/ rheumatology/kep062. Epub 2009 Apr 9.

Асеева ЕА, Соловьев СК, Клюквина НГ и др. Необратимые органные повреждения в когорте пациентов с системной красной волчанкой (РЕНЕС-САНС). Научно-практическая ревматология. 2016(54)4:404–11. [Aseeva EA, Solovyev SK, Klyukvina NG, et al. Irreversible organ damages in a cohort of patients with systemic lupus erythematosus (RENAISSANCE). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(4):404-11 (In Russ.)]. doi: 10.14412/1995-4484-2016-404-411

Zen M, Iaccarino L, Gatto M, et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis. 2015 Dec;74(12):2117-22. doi: 10.1136/annrheumdis-2015-207347. Epub 2015 Jul 29.

Ugarte-Gil MF, Burgos PI, Alarcon GS. Treat to target in systemic lupus erythematosus: a commentary. Clin Rheumatol.

Aug;35(8):1903-1907. doi: 10.1007/ s10067-016-3346-2. Epub 2016 Jul 12.

Van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-67. doi: 10.1136/ annrheumdis-2013-205139.

Соловьев СК, Асеева ЕА, Попкова ТВ и др. Стратегия лечения системной красной волчанки «до достижения цели» (Treat-to-Target SLE). Pекомендации международной рабочей группы и комментарии российских экспертов. Научно-практическая ревматология. 2015;53(1):9-16 [Soloviev SK, Aseeva EA, Popkova TV, et al. Treat-to-Target SLE recommendations from the International Task Force and Russian experts’ commentaries. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(1):9-16 (In Russ.)]. doi: 10.14412/ 1995-4484-2015-9-16

Mok CC. Current role of rituximab in systemic lupus erythematosus. Int J Rheum Dis. 2015;18(2):154-63. doi: 10.1111/1756-185X.12463.

Насонов ЕЛ, редактор. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Москва: ИМА-ПРЕСС; 2012. С. 119–52. [Nasonov EL, editor. Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-В-cellular therapy in rheumatology: focus on ritukximab]. Moscow: IMA-PRESS; 2012. P. 119–52.

Gracia-Tello B, Ezeonyeji A, Isenberg D. The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness. Lupus Sci Med. 2017;4(1):e000182. doi: 10.1136/lupus-2016-000182.

Aguiar R, Araujo C, Martines-Coelho G, Isenberg D. Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience Over 14 Years. Arthritis Care Res (Hoboken). 2017 Feb;69(2):257-262. doi: 10.1002/acr.22921.

Tanaka Y, Takeuchi T, Miyasaka N, et al. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Mod Rheumatol. 2016;26(1): 80-6. doi: 10.3109/14397595.2015.1060665. Epub 2015 Aug 19.

Iaccarino L, Bartoloni E, Carli L, et al. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clin Exp Rheumatol. 2015 Jul-Aug;33(4):449-56. Epub 2015 Jun 8.

Цанян МЭ, Соловьев СК, Торгашина АВ и др. Эффективность терапии ритуксимабом у больных рефрактерной к стандартной терапии системной красной волчанкой при длительном динамическом наблюдении. Научно-практическая ревматология. 2014;(52)2:159-68. [Tsanyan ME, Soloviev SK, Torgashina AV, et al. Rituximab treatment efficacy in patients with systemic lupus erythematosus refractory to stan-dart therapy in the long-term follow-up. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(2): 159-68. (In Russ.)]. doi: 10.14412/1995-4484-2014-159-168.

Moroni G, Raffiotta F, Trezzi B, et al. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology (Oxford). 2014 Sep;53(9):1570-7. doi: 10.1093/rheumatology/ket462. Epub 2014 Feb 6.

Condon MB, Damien A, Pepper R, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013 Aug;72(8):1280-6. doi:10.1136/annrheumdis-2012-202844. Epub 2013 Jun 5.

Jonsdottir T, Zickert A, Sundelin B, et al. Long-term follow-up in lupus nephritis patients treated with rituximab: clinical and histopathological response. Rheumatology (Oxford). 2013 May;52(5):847-55.

doi: 10.1093/rheumatology/kes348. Epub 2013 Jan 3.

Duxbury B, Combescure C, Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus. 2013 Dec;22(14):1489-503. doi: 10.1177/0961203313509295. Epub 2013 Oct 17.

Weidenbusch M, Rommele C, Schrottle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 2013 Jan; 28(1):106-11. doi: 10.1093/ndt/gfs285. Epub 2012 Jul 3.

Diaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2012 Mar;11(5):357-64. doi: 10.1016/j.autrev. 2011.10.009. Epub 2011 Oct 18.

Pepper R, Griffith M, Kirwan C, et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant. 2009 Dec;24(12):3717-23. doi: 10.1093/ndt/ gfp336. Epub 2009 Jul 17.

Roccatello D, Sciascia S, Baldovino S, et al. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment: clinical response compared to literature and immunological reassessment. Autoimmun Rev. 2015 Dec; 14(12):1123-30. doi: 10.1016/j.autrev.2015.07. 017. Epub 2015 Aug 2.

Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002 Aug;46(8):2121-31. doi:10.1002/ art.10461.

Ezeonyeji AN, Isenberg DA. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regime. Rheumatology (Oxford). 2012; 51(3):476-81. doi: 10.1093/rheumatology/ ker337.

Tedeschi B, Arnaud L, Hie M, et al. Successful treatment of combined proliferative and membranous lupus nephritis usind a full corticosteroid-free regimen. Ann Rheum Dis. 2014 Feb;73(2):474-5. doi: 10.1136/ annrheumdis-2013-204385. Epub 2013 Sep 3.

Gatto M, Kiss E, Naparstek Y, et al. In-/off-label use of biologic therapy in systemic lupus erythematosus. BMC Med. 2014 Feb 17;12:30. doi: 10.1186/1741-7015-12-30.

Li EK, Tam LS, Zhu TY, et al. Is combination rituximab with cyclophosphamide better than Rituximab alone in the treatment of lupus nephritis? Rheumatology (Oxford). 2009;48(8):892-8. doi: 10.1093/rheumatology/kep124.

Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus. 2011 Jun;20(7): 709-16. doi: 10.1177/0961203310395802. Epub 2011 Apr 8.

Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012 Apr;64(4): 1215-26. doi: 10.1002/art.34359. Epub 2012 Jan 9.

Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012 Jun;64(6):797-808.

doi: 10.1002/acr.21664.

Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012 Nov;71(11):1771-82. doi: 10.1136/annrheumdis-2012-201940. Epub 2012 Jul 31.

Kleinmann JF, Tubach F, Le Guern V, et al. International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmun Rev. 2017 Jun;16(6):650-657. doi: 10.1016/j.autrev.2017.04.011. Epub 2017 Apr 18.

Cobo-Ibanez T, Loza-Santamaria E, Pego-Reigosa JM, et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum. 2014 Oct;44(2): 175-85. doi: 10.1016/j.semarthrit.2014.04.002. Epub 2014 Apr 13.

Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007 Apr;66(4):470-5. Epub 2006 Nov 15. doi: 10.1136/ard.2006.057885.

Narvaez J, Rios-Rodriguez V, de la Fuente D, et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum. 2011 Dec; 41(3):364-72. doi: 10.1016/j.semarthrit.2011.06.004. Epub 2011 Aug 27.

Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-Beekman GM. Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. Drugs. 2016 Mar; 76(4):459-83. doi: 10.1007/s40265-015-0534-3.

Vital EM, Wittmann M, Edward S, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheumatol. 2015 Jun;67(6):1586-91.

doi: 10.1002/art.39085.

Urowitz MB, Gladman DD. How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology (Oxford). 2000 Mar;39(3):238-44. doi:10.1093/rheumatology/39.3.238

Vital EM, Dass S, Buch MH, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 2011 Oct;63(10):3038-47. doi: 10.1002/art.30466.

Капланов КД, Зарицкий АЮ, Алексеев СМ и др. Начало эры применения биоаналогов моноклональных антител в онкологии: современные международные рекомендации и результаты исследования первого российского биоаналога ритуксимаба у больных В-клеточной неходжкинской лимфомой. Современная онкология. 2014;(16):38-44 [Kaplanov KD, Zaritskii AYu, Alekseev SM, et al. Beginning of an era of application of biosimilars of monoclonal antibodies in oncology: Current international recommendations and findings of the first Russian biosimilars rituximab in patients with B-cell non-Hodgkin's lymphoma. Sovremennaya Onkologiya. 2014;(16):38-44. (In Russ.)].

Насонов ЕЛ, Зонова ЕВ, Иванова ОН и др. Результаты сравнительного клинического исследования III фазы препаратов ритуксимаба (Ацеллбия® и Мабтера®) при ревматоидном артрите (исследование BIORA). Научно-практическая ревматология. 2016(54)5:510–9. [Nasonov EL, Zonova EV, Ivanova ON, et al. The results of a phase III comparative clinical trial of rituximab (Acellbia® and MabThera®) in rheumatoid arthritis (the BIORA study). Nauchno-Prakticheskaya Revmatologiya = Rheumato-logy Science and Practice. 2016;54(5):510-9 (In Russ.)]. doi: http://dx.doi.org/10.14412/ 1995-4484-2016-510-519

The authors declare that there are no conflicts of interest present.